Log In
BCIQ
Print this Print this
 

Palexia (Tapentadol IR, Nucynta IR) (formerly CG5503, R331333)

  Manage Alerts
Collapse Summary General Information
Company Gruenenthal Group
DescriptionMu opioid receptor (OPRM1; MOR) agonist and norepinephrine reuptake inhibitor
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor agonist
Therapeutic Modality 
Latest Stage of DevelopmentMarketed
Standard IndicationPain
Indication DetailsTreat chronic pain; Treat moderate to severe acute pain; Treat pain; Treat pain following bunionectomy surgery; Treat pain following primary joint replacement surgery for end-stage joint disease
Regulatory Designation
PartnerDepomed Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$2,900.0M

$2,900.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/07/2015

$1,800.0M

$1,800.0M

0

01/15/2015

$1,100.0M

$1,100.0M

0

Get a free BioCentury trial today